Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to determine the single-dose bioequivalence of the test
product, a potential generic 40 mg pantoprazole delayed-release tablet formulation, compared
with the reference product, a pantoprazole 40 mg delayed-release tablet formulation
(Protonix, Wyeth Pharmaceuticals), following a single dose in the fasted state.